Get the Stockscreener App
5.03
5.01%
0.24
Neonc Technologies Holdings Inc stock is traded at $5.03, with a volume of 102.37K.
It is up +5.01% in the last 24 hours and up +46.65% over the past month.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.
See More
Previous Close:
$4.79
Open:
$4.76
24h Volume:
102.37K
Relative Volume:
0.74
Market Cap:
$130.46M
Revenue:
$40,000
Net Income/Loss:
$-38.64M
P/E Ratio:
-2.7316
EPS:
-1.8414
Net Cash Flow:
$-22.21M
1W Performance:
+7.25%
1M Performance:
+46.65%
6M Performance:
-47.77%
1Y Performance:
-32.66%
1-Day Range:
$4.74
$5.195
1-Week Range:
$4.60
$5.195
52-Week Range:
$3.005
$12.99
Neonc Technologies Holdings Inc Stock (NTHI) Company Profile
Name
Neonc Technologies Holdings Inc
Sector
Industry
Phone
310 663 7831
Address
23975 PARK SORRENTO, CALABASAS
Compare NTHI vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTHI
Neonc Technologies Holdings Inc
|
5.03 | 118.27M | 40,000 | -38.64M | -22.21M | -1.8414 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Neonc Technologies Holdings Inc Stock (NTHI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-19-26 | Initiated | Alliance Global Partners | Buy |
| May-18-26 | Initiated | Maxim Group | Buy |
| Apr-24-26 | Initiated | BTIG Research | Buy |
Neonc Technologies Holdings Inc Stock (NTHI) Latest News
NeOnc Technologies (NASDAQ: NTHI) names Shomali to audit panel - Stock Titan
Neonc Technologies CEO Thomas C. Chen acquires $70,010 of common shares via IRA - Bitget
NeOnc Technologies Holds 2026 Annual Stockholder Meeting - The Globe and Mail
Neonc Technologies CEO Thomas Chen buys $69,997 in stock - Investing.com
Neonc Technologies CSO Thomas Chen buys $192,899 in stock - Investing.com
NeOnc Technologies (NTHI) CEO adds 12.8K-share IRA stake - Stock Titan
NeOnc Technologies (NTHI) investors approve equity plan, elect two directors - Stock Titan
Founder of NeOnc Technologies Holdings Thomas Chen Buys 1.0% More Shares - simplywall.st
NeOnc Technologies- Talk Is Cheap, Insider Buying Isn’t - Sahm
NeOnc Technologies (NTHI) CEO boosts stake with August open‑market buys - Stock Titan
Neonc Technologies CEO Amir Heshmatpour acquires $49,860 in stock - Investing.com
Neonc Technologies CEO Amir Heshmatpour acquires $49,860 in stock By Investing.com - Investing.com Canada
NeOnc (NTHI) CEO lifts direct stake to 3,096,000 shares - Stock Titan
NeOnc Technologies Holdings CEO Continues Open-Market Buying Following NEO100 Phase 2a Results and Elevated Short Interest - Quiver Quantitative
Neonc Technologies CEO buys $58,579 in company shares By Investing.com - Investing.com Australia
NTHI’s Nasdaq Advantage Takes on New Meaning After Its Breakthrough Phase 2a Results - Sahm
Neonc Technologies CEO buys $58,579 in company shares - Investing.com
NeOnc Technologies (NTHI) CEO adds stock in two August buys - Stock Titan
NeOnc Technologies Holdings, Inc. Common Stock (NASDAQ: NTHI) Stock Price, News & Analysis - Kalkine
Duos Technologies Group Sets Second Quarter 2026 Earnings Call for Monday, August 17, 2026 at 4:30 PM ET - Stocktwits
NeOnc Technologies Holdings' Phase 2a Results Strengthen the Case for Its Nasdaq-Backed Capital Strategy - Moomoo
NeOnc Technologies Holdings’ Phase 2a Results Strengthen the Case for Its Nasdaq-Backed Capital Strategy - Quiver Quantitative
NTHI's Nasdaq Advantage Takes on New Meaning After Its Breakthrough Phase 2a Results - Moomoo
NeOnc Technologies Holdings Inc (NTHI) (Q2 2026) Earnings Call Highlights: First Annual Meeting ... By GuruFocus - Investing.com Canada
NTHI: All proposals, including director elections and plan amendments, were approved without questions - TradingView
Maxim Group Maintains NeOnc Technologies(NTHI.US) With Buy Rating, Maintains Target Price $20 - Moomoo
NeOnc Reports 26.1-Month Median Overall Survival in Phase 2a Brain Cancer Trial - Minichart
NeOnc Technologies holds investor call to discuss Phase 2a NEO100-01 results By Investing.com - Investing.com Nigeria
Form 8K Neonc Technologies Holdings Inc For: 13 August By Investing.com - Investing.com Canada
NeOnc Technologies (NTHI) NEO100 Phase 2a Readout Clears Primary Endpoint, FDA Meeting Planned - kalkine.ca
The Nose Knows: Why NeOnc’s Patent Portfolio Could Make NTHI More Than a One-Drug Biotech - The Manila Times
NeOnc Technologies Holdings’ NEO100 Phase 2a Results Highlight Intranasal Brain-Delivery Platform Potential - Quiver Quantitative
NeOnc's Nasal Drug Delivery Strategy Reached a Brain-Cancer Trial - Stock Titan
Why is Neonc Technologies stock surging today? By Investing.com - Investing.com South Africa
Targeting The Mutant: NTHI’s NEO100 Data Could Open a New Front in the Fight Against Brain Cancer - The Manila Times
NeOnc Technologies Holdings Reports Positive Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma - Quiver Quantitative
NeOnc Technologies stock jumps on positive glioma trial data By Investing.com - Investing.com Australia
NeOnc Technologies shares jump after positive Phase 2a glioma results - Yahoo Finance
NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x - Yahoo Finance
Why is Neonc Technologies stock surging today? - Investing.com
$NeOnc Technologies (NTHI.US)$ $NTHI plans an FDA Type B meeting to align the registrational path, signaling trial for accelerated approval. Clinical breakthrough could unlock financing and partnerships for NTHI's funding, milestone payments and markers - Moomoo
NeOnc Technologies Reports Positive Phase 2a Glioma Results - TipRanks
Form 8K Neonc Technologies Holdings Inc For: 12 August By Investing.com - Investing.com India
NeOnc reports phase 2a glioma trial meets primary endpoint By Investing.com - Investing.com Australia
NeOnc reports phase 2a glioma trial meets primary endpoint - Investing.com
$NTHI Mr. Heshmatpour CEO invested nearly $1 million of personal capital into NeOnc shares. In recent Months, he has purchased over $500,000 in the open market, as reflected in Form 4 filings with the U.S. Securities and Exchange Commission, with furthe - Moomoo
NeOnc Technologies stock jumps on positive glioma trial data - Investing.com
NeOnc Technologies Reports Positive Phase 2a NEO100 Results; Median OS 26.09 Months, PFS-6 48.9% - TradingView
Why is NeOnc Technologies stock surging today? By Investing.com - Investing.com Canada
NeOnc Technologies Reports Positive Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma - The Manila Times
Neonc Technologies Holdings Inc Stock (NTHI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Neonc Technologies Holdings Inc Stock (NTHI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| CHEN THOMAS C | CEO |
Aug 14 '26 |
Buy |
3.85 |
33,787 |
130,002 |
581,059 |
| CHEN THOMAS C | CEO |
Aug 17 '26 |
Buy |
4.04 |
2,472 |
9,998 |
583,531 |
| Heshmatpour Amir F | CEO, President |
Aug 18 '26 |
Buy |
5.54 |
9,000 |
49,860 |
3,096,000 |
| Heshmatpour Amir F | CEO, President |
Aug 14 '26 |
Buy |
3.79 |
12,000 |
45,460 |
3,084,000 |
| Heshmatpour Amir F | CEO, President |
Aug 17 '26 |
Buy |
4.37 |
3,000 |
13,120 |
3,087,000 |
| Heshmatpour Amir F | President |
May 01 '26 |
Buy |
4.16 |
10,000 |
41,592 |
3,072,000 |
| Heshmatpour Amir F | President |
Apr 28 '26 |
Buy |
4.52 |
10,000 |
45,180 |
3,062,000 |
| Neman-Ebrahim Yousha | Chief Clinical Officer |
Apr 23 '26 |
Buy |
4.88 |
500 |
2,440 |
134,760 |
| Heshmatpour Amir F | President |
Apr 23 '26 |
Buy |
4.90 |
10,000 |
49,000 |
3,052,000 |
| SUH, DAVID JR. | Chief Accounting Officer |
Apr 09 '26 |
Buy |
5.00 |
200 |
1,000 |
111,866 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):